LifeMD, Inc. (NASDAQ: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at $499 per month.
Through LifeMD’s integration with NovoCare® Pharmacy, eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, now have direct access to all FDA-approved dose strengths of Ozempic® within LifeMD’s end-to-end virtual care platform.
LifeMD’s telehealth platform is seamlessly integrated with NovoCare® Pharmacy to provide easy, reliable access to Novo Nordisk’s FDA-approved GLP-1 medications, Ozempic® and Wegovy®, at the most competitive cash-pay price. Patients benefit from a comprehensive care journey that includes:
• Virtual consultations with LifeMD’s 50-state affiliated medical group,
• Ongoing clinical support from licensed providers,
• Access to nationwide diagnostic testing,
• Pharmacy coordination with fast, reliable shipping and real-time order tracking, and
• Simplified billing and payment options.
Said Justin Schreiber, Chairman and CEO of LifeMD, “By broadening the program to now include Ozempic®, in addition to Wegovy®, we’re strengthening our ability to deliver FDA-approved GLP-1 therapies at the most competitive self-pay prices on the market—within a seamless, clinically supported patient experience from prescription to fulfillment.”
LFMD grabbed 26 cents, or 4.1%, to $6.70.
